Securities Exchange Act of 1934

Armada Acquisition Corp. I Extends Deadline To Consummate Business Combination with Rezolve

Retrieved on: 
Friday, November 11, 2022
CEO, Form, Sale, Register, United States Army Acquisition Corps, Company, Failure, F-4, NASDAQ, Board, Suite, ACI Worldwide, Securities Exchange Act of 1934, Person, GLOBE, Director, Risk, Acquisition, Social media, Communication, SEC, Smartlink, Ashford, Prospectus, Securities Act of 1933, Private Securities Litigation Reform Act, Intention, AACI, Armada, Government Digital Service, SmartCode, COVID-19, Technology, Partnership, QR, SDK, Pharmaceutical industry, Financial services, Security (finance)

I (the Company or Armada) announced today that its Board has approved an automatic extension of the deadline for the Company to consummate the business combination with Rezolve Limited from November 17, 2022 to February 17, 2023.

Key Points: 
  • I (the Company or Armada) announced today that its Board has approved an automatic extension of the deadline for the Company to consummate the business combination with Rezolve Limited from November 17, 2022 to February 17, 2023.
  • The business combination between the Company and Rezolve remains subject to the satisfaction of customary closing conditions, including the approval of the stockholders of the Company.
  • Armada is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • I and Where to Find It
    This communication relates to the proposed business combination transaction among the Company and Rezolve and the other parties thereto.

Jeffs' Brands Reinforces its Brands for the Holiday Season with Potential High Profitability Products

Retrieved on: 
Friday, November 11, 2022
Form, Securities Act of 1933, Register, James v Redcats (Brands) Ltd, FBA, Company, Amazon Marketplace, Public expenditure, U.S. Securities and Exchange Commission, ROI, Securities Exchange Act of 1934, GLOBE, Technology, SEC, PETS, Forward-looking statement, FBM, Online shopping

Tel Aviv, Israel, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today announced a boost in its brands' products offering, launching new products in time for the holiday season.

Key Points: 
  • Tel Aviv, Israel, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the Company) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today announceda boost in its brands' products offering, launching new products in time for the holiday season.
  • The Company strengthens its brands' portfolio with 16 new products, available nowat its U.S. Amazon stores.
  • "Our goal is to rapidly grow our business by offering attractive products.
  • Jeffs' Brands Ltd is transforming the world of e-commerce by creating and acquiring products and turning them into market leaders, tapping into vast, unrealized growth potential.

FangDD Announces Board and Committee Changes

Retrieved on: 
Friday, November 11, 2022
FedEx, Audit committee, Company, Software as a service, Chief, Board, Financial compensation, Artificial intelligence, Professional Football Compensation Committee, Rule, Securities Exchange Act of 1934, GLOBE, Nasdaq, Technology, Solution, Terminology, China Europe International Business School, Forward-looking statement, Private Securities Litigation Reform Act, Board of directors, Citibank, Procter & Gamble, Procter, MBA, Audit, Management

These Board and committee changes became effective today.

Key Points: 
  • These Board and committee changes became effective today.
  • On behalf of the Board, I would like to thank Mr. Chen for his insights and contributions to FangDD and wish him all the best in his future endeavors, said Mr. Xi Zeng, the Chairman of the Board and the Chief Executive Officer of FangDD.
  • I would also like to warmly welcome Mr. Xie to the Board.
  • We believe Mr. Xies range of skills and rich knowledge of business operations will add significant value to the Board and enhance the overall governance and management of FangDD.

Gulf Resources Announces Rescheduled Conference Call to Discuss Third Quarter 2022 Results on Tuesday, Nov. 15, 2022 at 8:00 a.m. EST

Retrieved on: 
Friday, November 11, 2022
CEO, U.S. Securities and Exchange Commission, Energy Independence and Security Act of 2007, Natural gas, EST, DCHC, Agriculture, Company, Risk, Securities Exchange Act of 1934, Security (finance), GLOBE, Bromine, Technology, SHSI, SCHC, Trinidad and Tobago Securities and Exchange Commission, Securities Act of 1933, News, COVID-19, Industry, Limited, PRC

Accordingly, the company has rescheduled the call for 8:00 a.m. EST on Tuesday, Nov. 15, before the opening of the market.

Key Points: 
  • Accordingly, the company has rescheduled the call for 8:00 a.m. EST on Tuesday, Nov. 15, before the opening of the market.
  • To participate in this live conference call, please dial Toll Free +1888506-0062 five to ten minutes prior to the scheduled conference call time.
  • International callers should dial +1973-528 - 0011, and please reference to Gulf Resources or Participant Access Code: 105706 while dialing in.
  • Gulf Resources undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Nano Labs to Announce Third Quarter 2022 Financial Results on November 17, 2022

Retrieved on: 
Friday, November 11, 2022
Frost, U.S. Securities and Exchange Commission, Company, Frost & Sullivan, Securities Exchange Act of 1934, Security (finance), GLOBE, HPC, PIN, Terminology, HTC, Private Securities Litigation Reform Act, TBPS, Architecture, NA, Nasdaq, Time, Renewable energy, Internet service provider

HANGZHOU, China, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (we, the Company or Nano Labs), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the third quarter of 2022 before the U.S. market opens on Thursday, November 17, 2022.

Key Points: 
  • HANGZHOU, China, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (we, the Company or Nano Labs), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the third quarter of 2022 before the U.S. market opens on Thursday, November 17, 2022.
  • The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (9:30 pm Beijing Time) on November 17, 2022.
  • Upon registration, participants will receive the dial-in number and unique PIN, which can be used to join the conference call.
  • Nano Labs Ltd is a leading fabless integrated circuit (IC) design company and product solution provider in China.

Apexigen Announces New Data from a Phase 1/2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with First-Line Metastatic Melanoma at the SITC 2022 Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Safety, Drug Quality and Security Act, Toxic epidermal necrolysis, Death, Associate, SITC, Society, PD-L1, NASDAQ, Vaccination, Pembrolizumab, Securities Exchange Act of 1934, Cancer, Immunotherapy, Perception, Gene, Adoption, GLOBE, PD-1, Principal, University, SAN, Oncology, Patient, Annual general meeting, SEC, Melanoma, Macrophage, Securities Act of 1933, Tumor microenvironment, B cell, TME, Therapy, Nasdaq, Standard of care, ORR, Pharmaceutical industry, Vaccine

SAN CARLOS, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced new data from an ongoing Phase 2 investigator-sponsored trial evaluating intratumoral sotigalimab (sotiga), Apexigen’s CD40 agonist antibody, in combination with systemic pembrolizumab (anti-PD-1 antibody) in first-line metastatic melanoma. Results showed that the combination therapy was well-tolerated in the trial and an improved best overall response rate (ORR) was observed relative to the standard of care, pembrolizumab monotherapy. Broad innate and adaptive immune activation was observed in both local and distant (non-injected) lesions. The data were featured in an oral presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.

Key Points: 
  • The data were featured in an oral presentation at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting, taking place in Boston, Massachusetts from November 8-12, 2022.
  • Results from the ongoing Phase 2 trial of intratumoral sotigalimab and the PD-1 inhibitor pembrolizumab showed a promising ORR including responses achieved in PD-L1 negative tumors.
  • Key data and conclusions featured in the SITC presentation include:
    Safety and tolerability: Intratumoral administration of sotiga in combination with pembrolizumab was well-tolerated.
  • Efficacy: The objective response rate (ORR) was 47% (n=32) in all patients, including patients enrolled in the dose escalation portion of the trial.

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Clinical trial, HLA, Observation, Mouse, Result, Melanoma, Society for Immunotherapy of Cancer, Annual report, Society, SITC, MAGE-A1, Cancer, Antigen, PRAME, Private Securities Litigation Reform Act, TCR, Securities Exchange Act of 1934, Therapy, Analysis, Immunotherapy, Collection, Peptide, GLOBE, Research, Financial condition report, 23rd Street station (IND Eighth Avenue Line), Patient, Annual general meeting, Safety, COVID-19, Head, Growth, Nasdaq, Epitope, IND, Neoplasm, Medical imaging, Pharmaceutical industry, Vaccine, Company

WALTHAM, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • We are solving this problem by building a diverse collection of therapeutic TCRs to enable customized multiplexed TCR-T therapy.
  • The discovery of PRAME-specific TCRs and the observation that they synergize with our MAGE-A1-specific TCRs marks the next step in our solid tumor program.
  • We continue to focus on growing our ImmunoBank and pursuing our clinical and regulatory strategy to bring customized therapies to patients with a broad range of solid tumor malignancies.
  • Discovery of PRAME-specific TCR-T cell therapy candidates for the treatment of solid tumors, presented by Mollie Jurewicz, Ph.D.

Modiv Announces Initiation of Equity Analyst Coverage by Ladenburg Thalmann with a “Buy” Recommendation

Retrieved on: 
Friday, November 11, 2022
REIT, Finance, Professional Services, Commercial Building & Real Estate, Construction & Property, Securities Act of 1933, MDV, Company, Ladenburg Thalmann, Securities Exchange Act of 1934, Face, Research, SEC, REIT, Inc., Projection, Trust, NYSE, Industry, Financial services, Security (finance)

We are grateful to see additional independent institutional research analyst coverage and the positive affirmation of our Company, said Aaron Halfacre, Chief Executive Officer.

Key Points: 
  • We are grateful to see additional independent institutional research analyst coverage and the positive affirmation of our Company, said Aaron Halfacre, Chief Executive Officer.
  • Copies of the full analyst report can be obtained directly from Ladenburg Thalmann.
  • All reports on Modiv prepared by analysts represent the views of such analysts and are not necessarily those of Modiv.
  • Modiv Inc. is an internally managed REIT that acquires, owns and manages a diversified portfolio of single-tenant net-lease real estate.

INVESTOR ALERT: Enviva Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – EVA

Retrieved on: 
Friday, November 11, 2022
Class Action Lawsuit, Professional Services, Legal, Private Securities Litigation Reform Act, Lawyer, CASE, LP, Enviva, History, Securities Exchange Act of 1934, Company, Wood, SEC, News, Growth, NYSE, Enron, Tobacco

), the Enviva class action lawsuit charges Enviva and certain of its top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Enviva class action lawsuit charges Enviva and certain of its top executives with violations of the Securities Exchange Act of 1934.
  • THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Enviva securities during the Class Period to seek appointment as lead plaintiff in the Enviva class action lawsuit.
  • A lead plaintiff acts on behalf of all other class members in directing the Enviva class action lawsuit.
  • An investors ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Enviva class action lawsuit.

Goldman Sachs Asset Management Announces Share Repurchase Program for MLP and Energy Renaissance Fund and Quarterly Distribution of $0.200 Per Share

Retrieved on: 
Friday, November 11, 2022
Banking, Professional Services, Finance, Investment, Fund, MLP, Goldman Sachs asset management factor model, Sale, Program, Securities Exchange Act of 1934, Review, Goldman Sachs, Share repurchase, Income, Risk, Loss, GS, AUS, Goal, GER, Partnership, NYSE, NAV, Trustee, Security (finance), Financial adviser

Additionally, Goldman Sachs Asset Management, the investment adviser for the Fund, announced today that the Funds Board of Trustees has approved a share repurchase program for the Fund, effective from November 10, 2022 through November 10, 2023.

Key Points: 
  • Additionally, Goldman Sachs Asset Management, the investment adviser for the Fund, announced today that the Funds Board of Trustees has approved a share repurchase program for the Fund, effective from November 10, 2022 through November 10, 2023.
  • In addition, portfolio holdings as of September 30, 2022, as well as additional information regarding the Fund, can be accessed through the Goldman Sachs Asset Management Closed-End Fund landing page at www.GSAMFUNDS.com/cef.
  • Goldman Sachs MLP and Energy Renaissance Fund is a non-diversified, closed-end management investment company managed by Goldman Sachs Asset Managements Energy & Infrastructure Team, which is among the industrys largest MLP investment groups.
  • 1 Assets Under Supervision (AUS) includes assets under management and other client assets for which Goldman Sachs does not have full discretion.